Natural killer cell therapy and aerosol interleukin-2 for the treatment of osteosarcoma lung metastasis

Pediatric Blood and Cancer

Volumn 61, Issue 4, 2014, Pages 618-626

  Guma, Sergei R ^a   Lee, Dean A ^a   Yu, Ling ^a   Gordon, Nancy ^a   Hughes, Dennis ^a   Stewart, John ^a   Wang, Wei Lien ^a   Kleinerman, Eugenie S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Aerosol interleukin 2; Cytokines; Immunotherapy; Lung metastasis; Natural killer cells; Osteosarcoma

Indexed keywords

HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; INTERLEUKIN 2; NATURAL KILLER CELL RECEPTOR NKG2D; RECOMBINANT INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL EXPANSION; CELL MIGRATION; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY ASSAY; ELISA KIT; EX VIVO STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; INHALATIONAL DRUG ADMINISTRATION; LIMIT OF QUANTITATION; LUNG METASTASIS; LUNG NODULE; LYMPHOCYTE MIGRATION; MAJOR CLINICAL STUDY; MICROMETASTASIS; MOUSE; NATURAL KILLER CELL; NEBULIZER; NICK END LABELING; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; OSTEOSARCOMA LUNG METASTASIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; THERAPY EFFECT; TUMOR VOLUME;

AEROSOL INTERLEUKIN-2; CYTOKINES; IMMUNOTHERAPY; LUNG METASTASIS; NATURAL KILLER CELLS; OSTEOSARCOMA;

ADMINISTRATION, INHALATION; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CELL- AND TISSUE-BASED THERAPY; COMBINED MODALITY THERAPY; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; GPI-LINKED PROTEINS; HUMANS; IMMUNOENZYME TECHNIQUES; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; OSTEOSARCOMA; TUMOR CELLS, CULTURED;

EID: 84893510564     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24801     Document Type: Article

References (49)

1. Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. J Clin Oncol 2010; 28:2625-2634.
2. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: An analysis of 1, 702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-790.
3. Kager L, Zoubek A, Potschger U, et al. Primary metastatic osteosarcoma: Presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003; 21:2011-2018.
4. Kleinerman ES, Erickson KL, Schroit AJ, et al. Activation of tumoricidal properties in human blood monocytes by liposomes containing lipophilic muramyl tripeptide. Cancer Res 1983; 43:2010-2014.
5. Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol 1995; 18:93-99.
6. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival-A report from the Children's Oncology Group. J Clin Oncol 2008; 26:633-638.
7. Huang G, Yu L, Cooper LJ, et al. Genetically modified T cells targeting interleukin-11 receptor alpha-chain kill human osteosarcoma cells and induce the regression of established osteosarcoma lung metastases. Cancer Res 2012; 72:271-281.
8. Kiessling R, Klein E, Pross H, et al. " Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 1975; 5:117-121.
9. Long EO. Negative signaling by inhibitory receptors: The NK cell paradigm. Immunol Rev 2008; 224:70-84.
10. Bauer S, Groh V, Wu J, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285:727-729.
11. Cosman D, Mullberg J, Sutherland CL, et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001; 14:123-133.
12. Groh V, Rhinehart R, Secrist H, et al. Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci USA 1999; 96:6879-6884.
13. Heinemann A, Paschen A. Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D. Oncoimmunology 2012; 1:535-536.
14. de Kruijf EM, Sajet A, van Nes JG, et al. NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: An observational study. BMC Cancer 2012; 12:24.
15. Bottino C, Castriconi R, Pende D, et al. Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med 2003; 198:557-567.
16. Imai K, Matsuyama S, Miyake S, et al. Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: An 11-year follow-up study of a general population. Lancet 2000; 356:1795-1799.
17. Furue H, Matsuo K, Kumimoto H, et al. Decreased risk of colorectal cancer with the high natural killer cell activity NKG2D genotype in Japanese. Carcinogenesis 2008; 29:316-320.
18. Mamessier E, Pradel LC, Thibult ML, et al. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol 2013; 190:2424-2436.
19. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295:2097-2100.
20. Denman CJ, Senyukov VV, Somanchi SS, et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012; 7:e30264.
21. Rosenberg SA, Lotze MT, Muul LM, et al. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 1987; 316:889-8897.
22. Jia SF, Worth LL, Densmore CL, et al. Aerosol gene therapy with PEI: IL-12 eradicates osteosarcoma lung metastases. Clin Cancer Res 2003; 9:3462-3468.
23. Koshkina NV, Kleinerman ES. Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases. Int J Cancer 2005; 116:458-463.
24. Knight V, Kleinerman ES, Waldrep JC, et al. 9-Nitrocamptothecin liposome aerosol treatment of human cancer subcutaneous xenografts and pulmonary cancer metastases in mice. Ann N Y Acad Sci 2000; 922:151-163.
25. Khanna C, Anderson PM, Hasz DE, et al. Interleukin-2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases. Cancer 1997; 79:1409-1421.
26. Huland E, Heinzer H, Jorres RA, et al. Therapeutic approaches in metastatic renal cell carcinoma: Local immunotherapy. Urologe A 2004; 43:S140-S144.
27. Jia SF, Zwelling LA, McWatters A, et al. Interleukin-1 alpha increases the cytotoxic activity of etoposide against human osteosarcoma cells. J Exp Ther Oncol 2002; 2:27-36.
28. Gordon N, Arndt CA, Hawkins DS, et al. Fas expression in lung metastasis from osteosarcoma patients. J Pediatr Hematol Oncol 2005; 27:611-615.
29. Textor S, Durst M, Jansen L, et al. Activating NK cell receptor ligands are differentially expressed during progression to cervical cancer. Int J Cancer 2008; 123:2343-2353.
30. Rodriguez CO, Jr., Crabbs TA, Wilson DW, et al. Aerosol gemcitabine: Preclinical safety and in vivo antitumor activity in osteosarcoma-bearing dogs. J Aerosol Med Pulm Drug Deliv 2010; 23:197-206.
31. Shimizu K, Fields RC, Giedlin M, et al. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc Natl Acad Sci USA 1999; 96:2268-2273.
32. Leary SE, Wozniak AW, Billups CA, et al. Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Children's Research Hospital experience. Cancer 2013; 119:2645-2653.
33. McGilvray RW, Eagle RA, Watson NF, et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009; 15:6993-7002.
34. Holdenrieder S, Stieber P, Peterfi A, et al. Soluble MICB in malignant diseases: Analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother 2006; 55:1584-1589.
35. Paschen A, Sucker A, Hill B, et al. Differential clinical significance of individual NKG2D ligands in melanoma: Soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin Cancer Res 2009; 15:5208-5215.
36. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999; 17:501-506.
37. Dass CR, Ek ET, Choong PF. Human xenograft osteosarcoma models with spontaneous metastasis in mice: Clinical relevance and applicability for drug testing. J Cancer Res Clin Oncol 2007; 133:193-198.
38. Geryk-Hall M, Yang Y, Hughes DP. Driven to death: Inhibition of farnesylation increases Ras activity in osteosarcoma and promotes growth arrest and cell death. Mol Cancer Ther 2010; 9:1111-1119.
39. Lugini L, Cecchetti S, Huber V, et al. Immune surveillance properties of human NK cell-derived exosomes. J Immunol 2012; 189:2833-2842.
40. Huenecke S, Zimmermann SY, Kloess S, et al. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion. J Immunother 2010; 33:200-210.
41. Caligiuri MA, Murray C, Robertson MJ, et al. Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2. J Clin Invest 1993; 91:123-132.
42. Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 1985; 313:1485-1492.
43. Lorenz J, Wilhelm K, Kessler M, et al. Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: Toxicity, pharmacokinetics, and biological effects. Clin Cancer Res 1996; 2:1115-1122.
44. Heinzer H, Mir TS, Huland E, et al. Subjective and objective prospective, long-term analysis of quality of life during inhaled interleukin-2 immunotherapy. J Clin Oncol 1999; 17:3612-3620.
45. Huland E, Heinzer H. Renal cell carcinoma-Innovative medical treatments. Curr Opin Urol 2004; 14:239-244.
46. Hermann GG, Geertsen PF, von der Maase H, et al. Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma. Cancer Immunol Immunother 1991; 34:111-114.
47. Salvo G, Samoggia P, Masciulli R, et al. Interleukin-2 bolus therapy induces immediate and selective disappearance from peripheral blood of all lymphocyte subpopulations displaying natural killer activity: Role of cell adhesion to endothelium. Eur J Cancer 1992; 28A:818-825.
48. Aulitzky WE, Schuler M, Peschel C, et al. Interleukins. Clinical pharmacology and therapeutic use. Drugs 1994; 48:667-677.
49. Khanna C, Hasz DE, Klausner JS, et al. Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: Canine studies. Clin Cancer Res 1996; 2:721-734.